Novel Cancer Therapeutic SIM0610 Enters First-in-Human Trial
Shanghai Xianwei Medical Technology Co., Ltd. has initiated a first-in-human Phase 1 clinical trial (NCT07348211) of SIM0610, an investigational therapeutic targeting advanced solid tumors. The open-label study will evaluate the drug's safety and preliminary efficacy across multiple cancer types, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and hepatocellular carcinoma.
The trial will employ a dose-escalation design to assess SIM0610's safety profile, with an initial enrollment target of approximately 90 patients who have progressed after standard therapies. Researchers will track pharmacokinetic parameters, dose-limiting toxicities, and preliminary antitumor activity, collecting data through multiple dose levels and expansion cohorts.
Research Context
Despite the promising clinical investigation, significant uncertainties remain about SIM0610's precise molecular mechanism. No publicly available literature describes its biological target or specific modality, creating a notable knowledge gap in understanding the drug's potential therapeutic approach.